1. Scrip
  2. >>R&D

Positive Tagrisso Data Boost AstraZeneca's Lung Cancer Ambitions

 
• By Sukaina Virji

Latest data from AstraZeneca's Tagrisso will help the company to convert the lung cancer drug's conditional approvals to full approvals, and boost reimbursement negotiations.

Lung

AstraZeneca's Phase III AURA3 trial has met its primary endpoint, demonstrating better progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The AURA3 randomized trial assessed the efficacy and safety of Tagrisso (osimertinib) as a second-line treatment in more than 400 patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed following first-line EGFR tyrosine kinase inhibitor (TKI) therapy. Tagrisso also demonstrated a safety profile consistent with previous trials.

"[This data] means that AstraZeneca can now move to file for full approval of this treatment in the US and...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from R&D

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Pipeline Watch: Eight Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Alnylam Pairs Zilebesiran With Diuretics After Phase II Endpoint Miss In Hypertension

 
• By Manas Mishra

Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

More from Scrip

Sanofi’s Wayrilz Gets Out Of The Blocks With First US Approval For ITP

 
• By Alexandra Shimmings

The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.

Alnylam Pairs Zilebesiran With Diuretics After Phase II Endpoint Miss In Hypertension

 
• By Manas Mishra

Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Lilly’s orforglipron strong in diabetic obesity; Ascletis confident in oral GLP-1 challenger; myostatin drugs progress for obesity; an interview with OneSource’s CEO; and an analysis of Dupixent’s pipeline-in-a-product success.